Valganciclovir Shortage: What Providers and Prescribers Need to Know in 2026

Valganciclovir remains the cornerstone oral antiviral for CMV prophylaxis and treatment across solid organ transplant (SOT) and select hematopoietic cell transplant (HCT) populations. Yet clinicians regularly hear from patients who cannot fill their prescriptions. This article provides a clinical framework for understanding valganciclovir availability, anticipating supply disruptions, and supporting patient access in 2026.

Current Supply Status: What the FDA Data Shows

As of 2026, valganciclovir is not listed in the FDA Drug Shortages Database. Multiple generic manufacturers — including Camber Pharmaceuticals and others — produce valganciclovir 450 mg tablets and 50 mg/mL oral solution for the U.S. market, maintaining adequate national supply.

The clinical challenge is not a national shortage but a distribution bottleneck: valganciclovir is a specialty drug dispensed through a narrow, specialized pharmacy network. Most retail chain pharmacies do not routinely stock it, leading to patient-reported "unavailability" that is actually a local stocking issue, not a supply failure.

Why Valganciclovir Is a High-Risk Drug for Access Gaps

Several characteristics make valganciclovir particularly vulnerable to patient-level access failures:

• High retail price: $3,000–$3,400/month at retail for generic; $5,000+ for brand Valcyte. Pharmacies holding expensive specialty inventory they may not move quickly face financial disincentive to stock.
• Prior authorization burden: Most commercial payers and many Medicare Part D plans require PA for valganciclovir, adding administrative delay between prescription and dispensing.
• Specialty pharmacy dependency: Optimal access depends on the patient being enrolled in the appropriate specialty pharmacy — a process that sometimes fails at transitions of care (e.g., hospital discharge).
• Renal dose adjustments: Frequent dose modifications post-transplant create prescription confusion at the pharmacy level, sometimes triggering dispensing holds.

Clinical Consequences of Valganciclovir Access Gaps

Even brief interruptions in valganciclovir prophylaxis carry significant risk in high-risk CMV-seropositive or D+/R- patients. The clinical consequences of missed therapy can include:

• CMV reactivation and viremia, particularly in D+/R- recipients (>50% baseline CMV disease risk without prophylaxis)
• End-organ CMV disease: retinitis (vision loss or blindness), pneumonitis, colitis, hepatitis, encephalitis
• Indirect CMV effects: allograft rejection, increased opportunistic infections, increased mortality
• CMV resistance development when sub-therapeutic drug levels result from inconsistent dosing

Transition-of-Care Protocols to Prevent Gaps

Hospital-to-home transitions are the highest-risk point for valganciclovir access failures. Best practices include:

1. Pre-discharge pharmacy coordination: Confirm that the patient's outpatient pharmacy is enrolled to dispense valganciclovir before discharge, not after.
2. Bridge supply at discharge: Provide a 3–7 day supply from the inpatient pharmacy to cover the expected processing window for the outpatient specialty pharmacy.
3. Pre-authorization submission before discharge: Submit PA paperwork before the patient leaves, not when they call in frustrated.
4. Identify backup pharmacy sources: Know which specialty and local pharmacies in your area carry or can quickly order valganciclovir. Tools like medfinder can assist patients in locating these pharmacies in real time.

When to Consider Alternative Agents

For patients who are experiencing recurrent access failures, intolerable myelosuppression, or valganciclovir-resistant CMV, consider the following alternatives based on indication:

• Letermovir (Prevymis): Preferred for CMV prophylaxis switch in adult kidney transplant (D+/R-) and adult allogeneic HCT recipients who cannot tolerate valganciclovir. No cross-resistance. No myelosuppression. Not indicated for active CMV treatment.
• Maribavir (Livtencity): For treatment of CMV infection resistant/refractory to ganciclovir/valganciclovir/foscarnet/cidofovir in transplant recipients. 400 mg PO twice daily.
• IV Ganciclovir: For severe/life-threatening CMV disease, esophageal or CNS involvement, stem cell transplant recipients, or patients unable to take oral medications.
• Foscarnet (IV): Second-line for ganciclovir-resistant CMV or combined with ganciclovir for high-level resistance. Nephrotoxic; requires close monitoring.

A Tool for When Patients Can't Find Their Medication

When your patients call unable to fill their valganciclovir, medfinder for providers is a service that contacts local pharmacies on the patient's behalf to locate where the drug is in stock. This can reduce the frantic "I can't find my medication" calls your clinic receives and help patients find pharmacies faster.

See also: How to Help Your Patients Find Valganciclovir in Stock: A Provider's Guide.